Targeted drug delivery systems including liposomes, nanoparticles, drug-polymer conjugates, hydrogels and micelles have facilitated delivery of therapeutic and imaging agents to target sites in the body with minimal effects to healthy tissues. Therapeutics encapsulated within or conjugated to nanocarriers can be released in a sustained or triggered manner at the target site. These nanocarriers shield drugs from degradation and interact with targeted receptors to enhance cellular uptake. Advancements in stimuli-responsive targeted systems allow spatiotemporal control over drug release in response to specific physiological conditions like pH, enzymatic activity or temperature. Targeted therapies aid in overcoming toxicities, reducing dosage and increasing accumulation of drugs at disease sites.
The global Targeted Drug Delivery Market is estimated to be valued at US$ 761.95 Mn in 2023 and is expected to exhibit a CAGR of 9.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Nanocarriers are enabling targeted accumulation and controlled release of therapeutics at disease sites. Advancements in nanotechnology have facilitated development of stimuli-responsive drug delivery systems like hydrogels, liposomes and polymeric micelles that can selectively release drug payloads in response to specific biological triggers. Nanocarriers also aid in overcoming biodistribution challenges and enhancing cellular uptake of encapsulated drugs. Active targeting moieties like peptides, antibodies and aptamers are conjugated to nanocarriers to recognize receptors overexpressed on diseased cells and facilitates accumulation. These targeted nanomedicines accelerate development of personalized therapies with minimally invasive administration and localized drug action.
Porter’s Analysis
Threat of new entrants: The targeted drug delivery market requires massive R&D investments and regulatory approvals, which create high entry barriers for new players.
Bargaining power of buyers: There exist a large number of pharmaceutical players developing targeted drug delivery systems, reducing the bargaining power of buyers.
Bargaining power of suppliers: The suppliers of raw materials possess low bargaining power due to the availability of substitute materials suppliers.
Threat of new substitutes: New technologies and techniques for targeted drug delivery pose a threat of substitution.
Competitive rivalry: Intense competition exists among existing players to gain more market share.
Key Takeaways
The Global Targeted Drug Delivery Market Size is estimated to be valued at US$ 761.95 Mn in 2023 and is expected to exhibit a CAGR of 9.5% over the forecast period 2023 to 2030.
The North America region currently dominates the market owing to increased R&D investments and advanced healthcare infrastructure. Asia Pacific is projected to grow at fastest rate during the forecast period with increasing healthcare expenditures and expanding pharmaceutical industry in countries like China and India.
Key players operating in the targeted drug delivery market are AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca PLC, Boston Scientific Corporation, Becton, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC., Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M Company. These players are focusing on product launches and collaborations to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it